Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL413234 | 1.00 | FDFT1 (1.00) | FDFT1 | |
| Potassium Ion SCHEMBL417764 | 1.00 | FDFT1 (1.00) | FDFT1 | |
| Potassium Ion SCHEMBL413393 | 1.00 | FDFT1 (1.00) | FDFT1 | |
| Potassium Ion SCHEMBL414433 | 0.99 | FDFT1 (1.00) | FDFT1 | |
| Potassium Ion SCHEMBL412550 | 0.94 | FDFT1 (1.00) | FDFT1 | |
| Potassium Ion SCHEMBL412233 | 0.94 | FDFT1 (1.00) | FDFT1 | |
| Potassium Ion SCHEMBL416533 | 0.91 | FDFT1 (1.00) | FDFT1 | |
| Potassium Ion SCHEMBL417715 | 0.91 | FDFT1 (1.00) | FDFT1 | |
| Potassium Ion SCHEMBL417847 | 0.91 | FDFT1 (1.00) | FDFT1 | |
| Potassium Ion SCHEMBL418788 | 0.90 | FDFT1 (1.00) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367283-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | TSINGHUA UNIVERSITY (CN) | 2025-12-04 | — | — | US | disclosed |
| US-20250228841-A1 | COMPOSITIONS AFFECTING PIGMENT PRODUCTION AND METHODS FOR TREATMENT OF BACTERIAL DISEASES | APTORUM THERAPEUTICS LTD (HK) | 2025-07-17 | — | — | US | disclosed |
| CN-119097698-A | Inhibitors of mevalonate pathway as efficient vaccine adjuvants | 清华大学 | 2024-12-10 | — | — | CN | disclosed |
| CN-114848656-B | Inhibitors of mevalonate pathway as efficient vaccine adjuvants | 清华大学 | 2024-09-27 | — | — | CN | disclosed |
| CN-117486833-A | Compounds affecting pigment production and useful for treating bacterial diseases | 港大科桥有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-111108103-B | Compounds affecting pigment production and useful for treating bacterial diseases | 港大科桥有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-111094280-B | Compounds for the treatment of microbial infections and uses thereof | 港大科桥有限公司 | 2023-09-26 | — | — | CN | disclosed |
| US-20230278971-A1 | COMPOUNDS AFFECTING PIGMENT PRODUCTION AND METHODS FOR TREATMENT OF BACTERIAL DISEASES | VERSITECH LIMITED (HK) | 2023-09-07 | — | — | US | disclosed |
| US-20230041593-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF MICROBIAL INFECTIONS | VERSITECH LIMITED (HK) | 2023-02-09 | — | — | US | disclosed |
| US-20220387584-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | TSINGHUA UNIVERSITY (CN) | 2022-12-08 | — | — | US | disclosed |
| US-11446280-B2 | Compounds and methods for the treatment of microbial infections | VERSITECH LIMITED (CN) | 2022-09-20 | — | — | US | disclosed |
| CN-114848656-A | Inhibitors of the mevalonate pathway as highly effective vaccine adjuvants | 清华大学 | 2022-08-05 | — | — | CN | disclosed |
| US-11382971-B2 | Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant | TSINGHUA UNIVERSITY (CN) | 2022-07-12 | — | — | US | disclosed |
| CN-108289902-B | Inhibitors of the mevalonate pathway as highly effective vaccine adjuvants | 清华大学 | 2022-05-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367283-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | COASY, GGPS1, HMGCR | FDFT1 10/4885 |
| US-11382971-B2 | Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant | GGPS1, HMGCR, COASY | FDFT1 10/4885 |
| US-20230041593-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF MICROBIAL INFECTIONS | ELANE, FPR1, LTC4S | FDFT1 243/4885 |
| US-20250228841-A1 | COMPOSITIONS AFFECTING PIGMENT PRODUCTION AND METHODS FOR TREATMENT OF BACTERIAL DISEASES | TYR, FDFT1, XPA | FDFT1 2/4885 |
| US-20230278971-A1 | COMPOUNDS AFFECTING PIGMENT PRODUCTION AND METHODS FOR TREATMENT OF BACTERIAL DISEASES | TYR, ALAD, NQO1 | FDFT1 26/4885 |
| US-20220387584-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | COASY, GGPS1, HMGCR | FDFT1 10/4885 |
| US-11446280-B2 | Compounds and methods for the treatment of microbial infections | ELANE, FPR1, MPO | FDFT1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.